文献速递食管胃疾病与幽门螺杆菌

粪菌移植的长期安全性结局:香港粪菌移植登记处8年真实世界数据

Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-09-19

香港基于人群的粪菌移植登记处前瞻性纳入2013年6月至2022年4月接受粪菌移植的患者,随访中位30.3个月,共123例受试者接受510次粪菌移植。12个月后16例报告21种新发疾病,均判定与粪菌移植不太可能相关,复发性艰难梭菌感染患者中粪菌移植与匹配对照相比累积生存概率显著更高。

要点

  • 香港粪菌移植登记处前瞻性随访中位30.3个月,123例受试者共接受510次粪菌移植。
  • 12个月后16例报告21种新发疾病,均判定与粪菌移植不太可能相关。
  • 复发性艰难梭菌感染患者中粪菌移植与匹配对照相比累积生存概率显著更高。

核心结论

  • 来自亚洲首个粪菌移植登记处的前瞻性真实世界数据表明,粪菌移植具有极佳的长期安全性。
  • 粪菌移植后超过12个月发生新发疾病的风险低。

研究设计与样本

  • 研究招募2013年6月至2022年4月在香港因复发性艰难梭菌感染(CDI)及非CDI适应证(来自临床试验)接受粪菌移植的患者。
  • 共123例受试者(中位年龄53岁,范围13-90岁;52.0%男性)接受510次粪菌移植,前瞻性随访中位30.3个月(范围1-57.9个月)。
  • 通过电子病历获取新发医学诊断,并由临床医生独立裁定。
  • 复发性CDI患者的长期安全性与接受抗生素治疗的对照组进行比较。

主要发现

  • 粪菌移植最常见的适应证为2型糖尿病。
  • 粪菌移植后1个月内最常见的短期不良事件包括腹泻和腹痛。
  • 超过12个月的长期随访中,16例患者报告21种新发医学疾病,经电子病历确认。
  • 所有新发疾病均裁定为与粪菌移植不太可能相关。
  • 未出现炎症性肠病、肠易激综合征、过敏、糖尿病或精神障碍的新发病例。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Prospective long-term real-world safety data after fecal microbiota transplantation (FMT) remain limited. We reported long-term outcomes of FMT from a population-based FMT registry in Hong Kong. METHODS: We recruited patients undergoing FMT for recurrent Clostridioides difficile infection (CDI) and non-CDI indications from clinical trials, from June 2013 to April 2022 in Hong Kong. We captured data on demographics, FMT indications and procedures, clinical outcomes and short- to long-term safety. New medical diagnoses were obtained from electronic medical records and independently adjudicated by clinicians. Long-term safety in patients with recurrent CDI was compared with a control group treated with antibiotics. RESULTS: Overall, 123 subjects (median age 53 years, range 13-90 years; 52.0% male) underwent 510 FMTs and were prospectively followed up for a median of 30.3 (range, 1-57.9) months. The most common indication for FMT was type 2 diabetes mellitus. The most common short-term adverse events within 1 month of FMT included diarrhea and abdominal pain. At long-term follow-up beyond 12 months, 16 patients reported 21 new-onset medical conditions confirmed by electronic medical records. All were adjudicated to be unlikely to be related to FMT. There was no new case of inflammatory bowel disease, irritable bowel syndrome, allergy, diabetes mellitus, or psychiatric disorder. In a subgroup of patients with recurrent CDI, FMT was associated with a significantly higher cumulative survival probability compared with matched control subjects. CONCLUSIONS: This prospective real-world data from Asia's first FMT registry demonstrated that FMT has an excellent long-term safety profile. The risk of developing new medical conditions beyond 12 months after FMT is low.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Yau YK, Lau LHS, Lui RNS, et al. Long-Term Safety Outcomes of Fecal Microbiota Transplantation: Real-World Data Over 8 Years From the Hong Kong FMT Registry. Clin Gastroenterol Hepatol. 2023. PMID: 37734581. doi:10.1016/j.cgh.2023.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。